MetaVia Inc.
MTVA
Rang in aandelen
#32892
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Aandeelprijs
$1.28
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$8.43M
Verandering (1 dag)
4.07%
Verandering (1 jaar)
-21.47%
Land
US
Handel MetaVia Inc. (MTVA)
Categorie
Healthcare
Aandelsplitsingen voor MetaVia Inc. (MTVA)
Het aandeel MetaVia Inc. (symbool: MTVA) heeft in totaal 3 splitsingen ondergaan.
De meest recente splitsing vond plaats op Dec 21, 2023.
Eén aandeel MTVA dat vóór Dec 31, 2019 werd gekocht, staat nu gelijk aan 0.00016666666666667 aandelen MTVA.
De meest recente splitsing vond plaats op Dec 21, 2023.
Eén aandeel MTVA dat vóór Dec 31, 2019 werd gekocht, staat nu gelijk aan 0.00016666666666667 aandelen MTVA.
Lijst van aandelen splitsingen
| Jaar | Splitsing | Vermenigvuldiging | Cumulatieve vermenigvuldiging |
|---|---|---|---|
| 2023-12-21 | 1:8 | x0.125 | x0.00016666666666667 |
| 2022-09-13 | 1:30 | x0.033333333333333 | x0.0013333333333333 |
| 2019-12-31 | 1:25 | x0.04 | x0.04 |
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aantal aandelen splitsingen | Cumulatieve vermenigvuldiging | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
